HCPro, JustCoding Outpatient - 2018 Issue 22 (June)
Healthcare News: HRSA finalizes fifth delay to 340B rule on drug prices, civil monetary penalties
June 5th, 2018
Subscribe or sign in to view the full article.
Article Overview
This news article explains a federal postponement of a 340B-related final rule and places it in the broader context of drug pricing policy, civil monetary penalties, and stakeholder opposition. It is relevant to hospital compliance, pharmacy reimbursement, and healthcare policy professionals who track HRSA, HHS, and CMS actions affecting the 340B program.
Why This Topic Matters
The article highlights timing changes to a federal 340B regulatory action and the ongoing policy tension between manufacturer penalties, hospital concerns, and broader drug pricing changes in government programs. Readers following reimbursement, compliance, and regulatory updates will want to know how this delay affects the implementation timeline and related 340B oversight.
What You Will Learn
- The regulatory background of the 340B-related final rule
- Why the implementation date was delayed
- How HRSA and HHS characterize the need for further review
- How hospitals and the American Hospital Association responded
- How the 340B rule delay fits alongside other federal drug payment policy actions
Who Should Read This
- Hospital compliance staff
- Health system administrators
- Pharmacy reimbursement professionals
- Medical coding and billing professionals
- Healthcare policy analysts
- 340B program stakeholders
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com